Evidence map›Paper›PMID 33050010›Full record

ArticleInternational journal of molecular sciences2020

Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of

Thorsten H Ecke, Adisch Kiani, Thorsten Schlomm, Frank Friedersdorff, Anja Rabien, Klaus Jung, Ergin Kilic, Peter Boström, Minna Tervahartiala, Pekka Taimen and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Clever-1 positive macrophages in breast cancer.Breast cancer research and treatment · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Thorsten H EckeDepartment of Urology, HELIOS Hospital Bad Saarow, DE-15526 Bad Sarrow, Germany.ORCID 0000-0002-0787-2763
Adisch KianiDepartment of Urology, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, Germany.
Thorsten SchlommDepartment of Urology, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, Germany.
Frank FriedersdorffDepartment of Urology, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, Germany.
Anja RabienDepartment of Urology, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, Germany.
Klaus JungDepartment of Urology, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, DE-10098 Berlin, Germany.
Ergin KilicInstitute of Pathology, DE-51375 Leverkusen, Germany.
Peter BoströmDepartment of Urology, Turku University Hospital, FI-20521 Turku, Finland.
Minna TervahartialaMediCity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, FI-20520 Turku, Finland.
Pekka TaimenInstitute of Pathology, Turku University Hospital, FI-20521 Turku, Finland.ORCID 0000-0001-8849-4604
Jan GleichenhagenInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, DE-44789 Bochum, Germany.ORCID 0000-0003-0221-2974
Georg JohnenInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, DE-44789 Bochum, Germany.ORCID 0000-0002-3773-5946
Thomas BrüningInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University Bochum, DE-44789 Bochum, Germany.
Stefan KochBrandenburg Medical School, DE-14770 Brandenburg, Germany.
Jenny RoggischInstitute of Pathology, HELIOS Hospital Bad Saarow, DE-15526 Bad Sarrow, Germany.
Ralph M WirtzSTRATIFYER Molecular Pathology GmbH, DE-50935 Cologne, Germany.
Humboldt-Universität zu Berlin · DEHelios Hospital Bad Saarow · DEInstitute for Prevention and Occupational Medicine · DETurku University Hospital · FIKlinikum Leverkusen · DEUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBladder cancer is a heterogeneous malignancy. Therefore, it is difficult to find single predictive markers. Moreover, most studies focus on either the immunohistochemical or molecular assessment of tumor tissues by next-generation sequencing (NGS) or PCR, while a combination of immunohistochemistry (IHC) and PCR for tumor marker assessment might have the strongest impact to predict outcome and select optimal therapies in real-world application. We investigated the role of proliferation survivin/ MATERIALS AND

methodsWe used tissue microarrays (TMA) from n = 50 patients (38 males, 12 female) with muscle-invasive bladder cancer. All patients had been treated with radical cystectomy followed by adjuvant triple chemotherapy. Median follow-up time was 60.5 months. CD68, CLEVER-1, MAC387, and survivin protein were detected by immunostaining and subsequent visual inspection.

resultsNuclear staining rather than cytoplasmic staining of survivin predicted DSS as a single marker with high levels of survivin being associated with better PFS and DSS upon adjuvant chemotherapy (

conclusionsFor muscle-invasive bladder cancer patients, the proliferative activity as determined by the nuclear staining of survivin or RT-qPCR on the basis of molecular subtype characteristics outperforms single marker detections and single technology approaches. Infiltration by macrophages detected by IHC or PCR is associated with worse outcome in defined subsets of tumors. The limitations of this study are the retrospective nature and the limited number of patients. However, the number of molecular markers has been restricted and based on predefined assumptions, which resulted in the dissection of muscle-invasive disease into tumor-biological axes of high prognostic relevance, which warrant further investigation and validation.

Indexed as

AgedAged, 80 and overBiomarkers, TumorChemotherapy, AdjuvantDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansImmunohistochemistryKeratin-20Keratin-5MacrophagesMaleMiddle AgedPrognosisBiomarkers, TumorBIRC5 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesKeratin-20Keratin-5KRT20 protein, humanKRT5 protein, humanRNA, MessengerSurvivinadjuvant chemotherapyBIRC5bladder cancerERBB2KRT20macrophageMIBCpredictionRT-qPCRsurvivalsurvivin

Identifiers

PMID33050010
PMCPMC7582791
OpenAlexW3092406735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.